Listed

Amphastar Pharmaceuticals, Inc.: Form 10-Q for the period ended Sep 30, 2019

Filed with the SEC on Nov 8, 2019 and accepted by EDGAR at Nov 8, 2019, 17:06 ET.

Share

Management's discussion and analysis

As filed, 35,035 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following is a discussion and analysis of the consolidated operating results, financial condition, liquidity and cash flows of our company as of and for the periods presented below. The following discussion and analysis should be read in conjunction with the “Condensed Consolidated Financial Statements” and the related notes thereto included in this Quarterly Report on Form 10-Q, or Quarterly Report. This discussion contains forward-looking statements that are based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. Actual results could differ materially from those discussed in or implied by forward-looking statements. These risks, uncertainties, and other factors include, among others, those identified under the “Special Note About Forward-Looking Statements,” above and described in greater detail elsewhere in this Quarterly Report and in our Annual Report on Form 10-K for the year ended December 31, 2018, particularly in Item 1A. “Risk Factors”.

Overview

We are a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing and selling technically challenging generic and proprietary injectable, inhalation and intranasal products as well as insulin API products. We currently manufacture and sell over 20 products. In November 2018, the FDA granted over-the-counter approval for our NDA for Primatene® Mist in a new CFC-free formulation.

We are currently developing a portfolio of 15 generic abbreviated new drug applications, or ANDAs, three biosimilar product candidates and four proprietary product candidates, which are in various stages of development and target a variety of indications. Five of the ANDAs and one new drug application, or NDA, are currently on file with the FDA.

Our largest products by net revenues currently include enoxaparin sodium injection, naloxone hydrochloride injection, lidocaine jelly and sterile solution, phytonadione, medroxyprogesterone acetate, and Primatene® Mist. We launched Primatene® Mist in the fourth quarter of 2018.

To complement our internal growth and expertise, we have made several strategic acquisitions of companies, products and technologies. These acquisitions collectively have strengthened our core injectable and inhalation product technology infrastructure by providing additional manufacturing, marketing, and research and development capabilities including the ability to manufacture raw materials, APIs and other components for our products.

Included in these acquisitions are marketing authorizations for 33 products in the UK, Ireland, Australia, and New Zealand, representing 11 different injectable chemical entities, from UCB Pharma GmbH. We are in the process of transferring the manufacturing of these products to our facilities in California, which will require approvals from the UK Medicines and Healthcare products Regulatory Agency before we can relaunch the products.

In July 2018, our Chinese subsidiary, ANP, completed a private placement of its common equity interest and received approximately $56.3 million of cash proceeds. We have retained approximately 58% of the equity interest in ANP following the private placement. ANP’s net income or loss after July 2, 2018, is attributed to us in accordance with our equity interest of approximately 58% in ANP.

On May 20, 2019, we entered into a settlement relating to the enoxaparin patent and antitrust litigation with Momenta Pharmaceuticals, Inc. and Sandoz Inc. Pursuant to the settlement agreement, the plaintiffs paid us $59.9 million on June 27, 2019. For more information regarding the enoxaparin patent and antitrust litigation, see Note 19 to the condensed consolidated financial statements for more information regarding litigation matters.

Business Segments

As of September 30, 2019, our performance is assessed and resources are allocated based on the following two reportable segments: (1) finished pharmaceutical products and (2) API products. The finished pharmaceutical products segment manufactures, markets, and distributes enoxaparin, naloxone, phytonadione, lidocaine, medroxyprogesterone acetate, Primatene® Mist, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Information reported herein is consistent with how it is reviewed and evaluated by our chief operating decision maker. Factors used to identify our segments include markets, customers and products. (see Note 5 to the condensed consolidated financial statements for more information regarding our segment reporting).

Results of Operations

Three Months Ended September 30, 2019 Compared to Three Months Ended September 30, 2018

Net revenues

(in thousands)

Net revenues Three Months Ended September 30, 2019 2018 Change Dollars%
Finished pharmaceutical products $75,729 $71,767 $3,962 6%
API 4,408 3,776 632 17%
Total net revenues $80,137 $75,543 $4,594 6%
Cost of revenues
Finished pharmaceutical products $40,737 $41,196 $(459) (1)%
API 4,148 5,087 (939) (18)%
Total cost of revenues $44,885 $46,283 $(1,398) (3)%
Gross profit $35,252 $29,260 $5,992 20%
as % of net revenues 44% 39%

The increase in net revenues of finished pharmaceutical products for the three months ended September 30, 2019 was primarily due to the following changes:

(in thousands)

Finished pharmaceutical products net revenues Three Months Ended September 30, 2019 2018 Change Dollars%
Lidocaine $11,670 $9,875 $1,795 18%
Phytonadione 10,916 8,968 1,948 22%
Naloxone 10,613 9,432 1,181 13%
Enoxaparin 9,573 18,564 (8,991) (48)%
Medroxyprogesterone 7,879 7,552 327 4%
Epinephrine 3,756 1,881 1,875 100%
Primatene® Mist 3,654 — 3,654 N/A
Other finished pharmaceutical products 17,668 15,495 2,173 14%
Total finished pharmaceutical products net revenues $75,729 $71,767 $3,962 6%

The increase in sales of lidocaine was driven equally by a higher average selling price and higher unit volumes, with each factor having an impact of $0.9 million. The increase in sales of phytonadione during the third quarter of 2019 was driven by a higher average selling price. The increase in sales of epinephrine and naloxone were both primarily driven by higher unit volumes. Other finished pharmaceutical products sales increased primarily due to higher unit sales volumes of atropine, calcium chloride and dextrose, which were in high demand due to market shortages. Enoxaparin sales decreased due to lower unit volumes as a result of increased competition.

We anticipate that sales of naloxone, enoxaparin, and medroxyprogesterone will continue to fluctuate in the future as a result of competition.

Sales of API primarily depend on the timing of customer purchases. In August 2019, we amended the Supply Agreement with MannKind Corporation, or MannKind, whereby MannKind’s aggregate total commitment of RHI API under the Supply Agreement was modified and extended for an additional two years through 2026, which timeframe would have previously lapsed after calendar year 2024. MannKind has agreed to pay us an amendment fee of $2.75 million. We recognized the first payment of the amendment fee of $1.5 million in net revenues during the three months ended September 30, 2019. The remaining balance of the amendment fee is due in December 2019.

We anticipate that sales of API will continue to fluctuate and may decrease due to the inherent uncertainties related to sales to MannKind. In addition, most of our API sales are denominated in euros, and the fluctuation in the value of the euro versus the U.S. dollar has had, and will continue to have, an impact on API sales revenues in the near term.

A significant portion of our customer shipments in any period relate to orders received and shipped in the same period, generally resulting in low product backlog relative to total shipments at any time. We had no significant backlog as of September 30, 2019. Historically, our backlog has not been a meaningful indicator in any given period of our ability to achieve any particular level of overall revenue or financial performance.

Gross margins

The launch of Primatene® Mist, which is a higher margin product, as well as the higher average selling price of phytonadione, helped increase our gross margins for the third quarter of 2019. Gross margins for Primatene® Mist were magnified by the use of API and components which were expensed to pre-launch inventory in prior years.

The cost of heparin, which is the starting material for enoxaparin, has increased and is expected to increase further, putting downward pressure on our gross margins. However, we believe that this trend will be offset by sales of our higher-margin products, such as medroxyprogesterone, isoproterenol and Primatene® Mist, which were launched over the past two years.

Selling, distribution and marketing, and general and administrative

(in thousands)

Three Months Ended September 30, 2019 2018 Change Dollars%
Selling, distribution, and marketing $3,221 $1,963 $1,258 64%
General and administrative $11,021 $13,407 $(2,386) (18)%

The increase in selling, distribution, and marketing expenses was primarily due to marketing expenses related to Primatene® Mist, including the cost of a television and radio marketing campaign which began in July 2019. The decrease in general and administrative expense was primarily due to a decrease in legal expenses as a result of the enoxaparin patent and antitrust litigation settlement (see Note 19 to the condensed consolidated financial statements for more information regarding litigation matters).

We expect that selling, distribution and marketing expenses will increase due to the increase in marketing expenditures for Primatene® Mist. We expect that general and administrative expenses will increase on an annual basis due to increased costs associated with ongoing compliance with public company reporting obligations and an increase in legal fees associated with patent challenges.

Research and development

(in thousands)

Three Months Ended September 30, 2019 2018 Change Dollars%
Salaries and personnel-related expenses $6,979 $4,313 $2,666 62%
Clinical trials 2,238 193 2,045 1,060%
FDA fees 194 229 (35) (15)%
Testing, operating and lab supplies 4,770 4,286 484 11%
Depreciation 2,171 1,291 880 68%
Other expenses 2,254 1,028 1,226 119%
Total research and development expenses $18,606 $11,340 $7,266 64%

Research and development costs consist primarily of costs associated with the research and development of our product candidates including the cost of developing APIs. We expense research and development costs as incurred.

Salaries and personnel-related expenses as well as depreciation expense increased during the third quarter of 2019 primarily due to API and key component development at our ANP facility. Clinical trial expense increased due to external studies related to our generic product pipeline, primarily for our inhalation ANDAs. Testing, operating and lab supplies increased due to expenditures on materials for our pipeline products.

We have made, and expect to continue to make, substantial investments in research and development to expand our product portfolio and grow our business. We expect that research and development expenses will increase on an annual basis due to increased clinical trial costs related to our biosimilar and inhalation product candidates. These expenditures will include costs of APIs developed internally as well as APIs purchased externally, the cost of purchasing reference listed drugs and the costs of performing the clinical trials. As we undertake new and challenging research and development projects, we anticipate that the associated costs will increase significantly over the next several quarters and years.

Income tax provision

(in thousands)

Three Months Ended September 30, 2019 2018 Change Dollars%
Income tax provision $598 $958 $(360) NM
Effective tax rate 38% 37%

The difference in income tax provision was primarily due to differences in pre-tax income positions.

Nine Months Ended September 30, 2019 Compared to Nine Months Ended September 30, 2018

Net revenues

(in thousands)

Net revenues Nine Months Ended September 30, 2019 2018 Change Dollars%
Finished pharmaceutical products $224,003 $188,125 $35,878 19%
API 14,971 16,851 (1,880) (11)%
Total net revenues $238,974 $204,976 $33,998 17%
Cost of revenues
Finished pharmaceutical products $122,159 $110,269 $11,890 11%
API 18,273 22,411 (4,138) (18)%
Total cost of revenues $140,432 $132,680 $7,752 6%
Gross profit $98,542 $72,296 $26,246 36%
as % of net revenues 41% 35%

The increase in net revenues of the finished pharmaceutical products for the nine months ended September 30, 2019, was primarily due to the following changes:

(in thousands)

Finished pharmaceutical products net revenues Nine Months Ended September 30, 2019 2018 Change Dollars%
Enoxaparin $33,895 $34,286 $(391) (1)%
Lidocaine 33,731 29,667 4,064 14%
Phytonadione 33,477 28,955 4,522 16%
Naloxone 25,810 29,492 (3,682) (12)%
Medroxyprogesterone 21,788 16,623 5,165 31%
Epinephrine 9,574 8,791 783 9%
Primatene® Mist 9,063 — 9,063 N/A
Other finished pharmaceutical products 56,665 40,311 16,354 41%
Total finished pharmaceutical products net revenues $224,003 $188,125 $35,878 19%

$2.3 million of the increase in sales of lidocaine was due to higher unit volumes, while the remainder was due to higher average selling prices. The increase in sales of phytonadione was primarily driven by a higher average selling price. The decrease in sales of naloxone was primarily driven by lower average selling prices, with an impact of $2.2 million, while volume reductions accounted for the remainder of the decrease. The increase in sales of medroxyprogesterone was due to increased unit sales as it was launched in the first quarter of 2018, therefore, the prior year did not have a full quarter of sales during the first quarter of 2018. Other finished pharmaceutical products sales increased primarily due to higher unit sales volumes of Cortrosyn®, atropine, calcium chloride, and dextrose, which were in high demand due to market shortages. Sales of isoproterenol, which we launched in the third quarter of 2018, also contributed to the increase in other finished pharmaceutical sales.

We anticipate that sales of naloxone, enoxaparin, and medroxyprogesterone will continue to fluctuate in the future as a result of competition.

Sales of API primarily depend on the timing of customer purchases. In August 2019, we amended the Supply Agreement with MannKind, and recognized the first payment of the amendment fee of $1.5 million in net revenues during the nine months ended September 30, 2019. The remaining balance of the amendment fee is due in December 2019.

We anticipate that sales of API will continue to fluctuate and may decrease due to the inherent uncertainties related to sales to MannKind. In addition, most of our API sales are denominated in euros, and the fluctuation in the value of the euros versus the U.S. dollar has had, and will continue to have, an impact on API sales revenues in the near term.

A significant portion of our customer shipments in any period relate to orders received and shipped in the same period, generally resulting in low product backlog relative to total shipments at any time. We had no significant backlog as of September 30, 2019. Historically, our backlog has not been a meaningful indicator in any given period of our ability to achieve any particular level of overall revenue or financial performance.

Gross margins

The launch of Primatene® Mist and an increase in sales of medroxyprogesterone and Cortrosyn®, which are higher margin products, as well as the higher average selling price of enoxaparin and phytonadione, helped increase our gross margins for the nine months ended September 30, 2019. Gross margins for Primatene® Mist were magnified by the use of API and components which were expensed to pre-launch inventory in prior years.

The cost of heparin, which is the starting material for enoxaparin, has increased and is expected to increase further, putting downward pressure on our gross margins. However, we believe that this trend will be offset by sales of our higher-margin products, such as medroxyprogesterone, isoproterenol, and Primatene® Mist, which were launched over the past two years.

Selling, distribution and marketing, and general and administrative

(in thousands)

Nine Months Ended September 30, 2019 2018 Change Dollars%
Selling, distribution, and marketing $9,354 $5,560 $3,794 68%
General and administrative $39,774 $36,074 $3,700 10%

The increase in selling, distribution, and marketing expenses was primarily due to marketing expenses related to Primatene® Mist, including the cost of a television marketing campaign which began in July 2019. The increase in general and administrative expense was primarily due to an increase in personnel-related expenses, as well as legal expenses (see Note 19 to the condensed consolidated financial statements for more information regarding litigation matters).

We expect that selling, distribution and marketing expenses will increase due to the increase in marketing expenditure for Primatene® Mist. We expect that general and administrative expenses will increase on an annual basis due to increased costs associated with ongoing compliance with public company reporting obligations and an increase in legal fees associated with patent challenges.

Research and development

(in thousands)

Nine Months Ended September 30, 2019 2018 Change Dollars%
Salaries and personnel-related expenses $19,621 $12,691 $6,930 55%
Pre-launch inventory 158 1,573 (1,415) (90)%
Clinical trials 5,471 2,219 3,252 147%
FDA fees 598 1,690 (1,092) (65)%
Testing, operating and lab supplies 11,220 15,349 (4,129) (27)%
Depreciation 6,447 3,852 2,595 67%
Other expenses 5,694 3,456 2,238 65%
Total research and development expenses $49,209 $40,830 $8,379 21%
  • 35-

Research and development costs consist primarily of costs associated with the research and development of our product candidates. We expense research and development costs as incurred.

Salaries and personnel-related expenses as well as depreciation expense increased during the nine months ended September 30, 2019 primarily due to API and key component development at our ANP facility. Clinical trial expense increased due to external studies related to our generic product pipeline, primarily for our inhalation ANDAs. These increases were partially offset by a decrease in pre-launch inventory compared to the same period last year relating to the production of Primatene® Mist in anticipation for the launch at the end of 2018. FDA fees decreased for the period, as we filed an NDA and ANDA for products we currently market or previously marketed under the grandfather exception in 2018.

We have made, and expect to continue to make, substantial investments in research and development to expand our product portfolio and grow our business. We expect that research and development expenses will increase on an annual basis due to increased clinical trial costs related to our biosimilar and inhalation product candidates. These expenditures will include costs of APIs developed internally as well as APIs purchased externally, the cost of purchasing reference listed drugs and the costs of performing the clinical trials. As we undertake new and challenging research and development projects, we anticipate that the associated costs will increase significantly over the next several quarters and years.

Other income (expenses), net

(in thousands)

Nine Months Ended September 30, 2019 2018 Change Dollars%
Other income (expenses), net $58,172 $(440) $58,612 NM

In June 2019, we recognized a gain of $59.9 million relating to our settlement of the enoxaparin patent and antitrust litigation with Momenta Pharmaceuticals, Inc. and Sandoz Inc. For more information regarding the enoxaparin patent and antitrust litigation, see Note 19 to the condensed consolidated financial statements for more information regarding litigation matters.

Income tax provision (benefit)

(in thousands)

Nine Months Ended September 30, 2019 2018 Change Dollars%
Income tax provision (benefit) $13,292 $(2,137) $15,429 NM
Effective tax rate 23% 20%

The difference in income tax provision (benefit) was primarily due to differences in pre-tax income (loss) positions.

Liquidity and Capital Resources

Cash Requirements and Sources

We need capital resources to maintain and expand our business. We expect our cash requirements to increase significantly in the foreseeable future as we sponsor clinical trials for, seek regulatory approvals of, and develop, manufacture and market our current development‑stage product candidates and pursue strategic acquisitions of businesses or assets. Our future capital expenditures include projects to upgrade, expand, and improve our manufacturing facilities in the United States, China, and France. Our cash obligations include the principal and interest payments due on our existing loans and lease payments, as described below and throughout this Quarterly Report. As of September 30, 2019, our foreign subsidiaries collectively held $33.4 million in cash and cash equivalents. Cash or cash equivalents held at foreign subsidiaries are not available to fund the parent company’s operations in the United States. We believe that our cash reserves, operating cash flows, and borrowing availability under our credit facilities will be sufficient to fund our operations for at least the next 12 months. We expect additional cash flows to be generated in the longer term from future product introductions, although there can be no assurance as to the receipt of regulatory approval for any product candidates that we are developing or the timing of any product introductions, which could be lengthy or ultimately unsuccessful.

We maintain a shelf registration statement on Form S-3 pursuant to which we may, from time to time, sell up to an aggregate of $250 million of our common stock, preferred stock, depositary shares, warrants, units, or debt securities. If we require or elect to seek additional capital through debt or equity financing in the future, we may not be able to raise capital on terms acceptable to us or at all. To the extent we raise additional capital through the sale of equity or convertible debt securities, the issuance of such securities will result in dilution to our stockholders. If we are required and unable to raise additional capital when desired, our business, operating results and financial condition may be adversely affected.

Working capital increased by $68.8 million to $182.3 million at September 30, 2019, compared to $113.5 million at December 31, 2018 as a result of the $59.9 million settlement received relating to the enoxaparin patent and antitrust litigation with Momenta Pharmaceuticals, Inc. and Sandoz Inc. For more information regarding the enoxaparin patent and antitrust litigation, see Note 19 to the condensed consolidated financial statements.

Cash Flows from Operations

The following table summarizes our cash flows used in operating, investing, and financing activities for the nine months ended September 30, 2019 and 2018:

(in thousands)

Statement of Cash Flow Data: Net cash provided by (used in) Nine Months Ended September 30, 2019 2018
Operating activities $36,110 $28,674
Investing activities (43,175) (33,385)
Financing activities 6,599 8,086
Effect of exchange rate changes on cash (260) (235)
Net increase (decrease) in cash, cash equivalents, and restricted cash $(726) $3,140

Sources and Use of Cash

Operating Activities

Net cash provided by operating activities was $36.1 million for the nine months ended September 30, 2019, which included net income of $45.8 million. Non-cash items were primarily comprised of $13.3 million of depreciation and amortization, and $13.0 million of share-based compensation expense.

Additionally, there was a net cash outflow from changes in operating assets and liabilities of $48.9 million which resulted from the decrease in accounts receivable, offset by an increase in inventory, as well as a decrease in accounts payable and accrued liabilities. The decrease in accounts receivable was due to the timing of sales in the quarter. The increase in inventory was partially due to increased purchases of raw materials and production of finished goods resulting in a net increase of $31.0 million of enoxaparin and a net increase of $8.9 million of Primatene® Mist inventory. We plan to utilize our deferred tax credits to offset a significant portion of the tax liability related to 2019 U.S. federal and California state taxable income. Accounts payable and accrued liabilities decreased primarily due to the timing of payments.

Net cash provided by operating activities was $28.7 million for the nine months ended September 30, 2018, which included net loss of $8.4 million. Non-cash items were primarily comprised of $12.1 million of depreciation and amortization, and $12.8 million of share-based compensation expense.

The increase in accounts receivable was due to an increase in sales. An increase in inventory, due to increased purchases of raw materials for enoxaparin and other products in the U.S., was partially offset by a decrease in finished RHI API at AFP. Accounts payable and accrued liabilities increased, primarily due to the timing of payments.

Investing Activities

Net cash used in investing activities was $43.2 million for the nine months ended September 30, 2019, primarily as a result of $33.1 million in purchases of property, plant, and equipment, which included $7.3 million incurred in the United States, $6.6 million in France, and $19.2 million in China. Additionally, we purchased $9.8 million in short-term investments.

Net cash used in investing activities was $33.4 million for the nine months ended September 30, 2018, primarily as a result of $37.2 million in purchases of property, machinery, and equipment, which included $12.3 million incurred in the United States, $8.6 million in France, and $16.3 million in China. The cash used was partially offset by the $4.4 million receipt of the remaining consideration of the sale of the various ANDAs in February 2017.

Financing Activities

Net cash provided by financing activities was $6.6 million for the nine months ended September 30, 2019, primarily as a result of the receipt of $18.3 million for ANP private placement, and $2.0 million in net proceeds received from our equity plans. This was partially offset by $8.5 million used to purchase treasury stock. Additionally, we made $5.2 million in principal payments on our long-term debt and lines of credit.

Net cash provided by financing activities was $8.1 million for the nine months ended September 30, 2018, primarily as a result of $26.2 million received from the ANP private placement, which was partially offset by $22.4 million used to purchase treasury stock. Additionally, we made $4.3 million in principal payments on our long-term debt, and drew down $8.0 million on the equipment line of credit from East West Bank, which is due December 2022.

Indebtedness

For more information regarding our outstanding indebtedness, see Note 13 of Notes to Condensed Consolidated Financial Statements of this Quarterly Report.

Contractual Obligations

There have been no material changes outside the ordinary course of our business in the contractual obligations disclosed in our Annual Report on Form 10-K for the year ended December 31, 2018, except that our outstanding debt obligations have changed as follows:

(in thousands)

September 30, 2019 December 31, 2018 Change
Short-term debt and current portion of long-term debt $6,969 $18,229 $(11,260)
Long-term debt 38,079 31,984 6,095
Total debt $45,048 $50,213 $(5,165)

As of September 30, 2019, we had $45.0 million in unused borrowing capacity under revolving lines of credit with Cathay Bank and East West Bank.

Critical Accounting Policies

The preparation of our condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes to the financial statements. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions. A summary of our critical accounting policies is presented in Part II, Item 7, of our Annual Report on Form 10-K for the year ended December 31, 2018.

There were no material changes to our critical accounting policies during the three and nine months ended September 30, 2019, other than the adoption of ASC 2016-02, Leases, or ASC 2016-02, using the alternative transition method. The results for the reporting period beginning after January 1, 2019, are presented in accordance with the new standard, although comparative information has not been restated and continues to be reported under the accounting standards and policies in effect for those periods.

Recent Accounting Pronouncements

For information regarding recent accounting pronouncements, see Note 2 to the condensed consolidated financial statements for more information regarding summary of Significant Accounting Policies.

Off-Balance Sheet Arrangements

We do not have any relationships or financial partnerships with unconsolidated entities, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts.

Government Regulation

The 340(B) Public Health Services drug pricing program provides drugs at reduced rates to certain qualifying customers. As of January 1, 2019, the program provided for increased discounts for certain products we sell, including Cortrosyn®.

Our products and facilities are subject to regulation by a number of federal and state governmental agencies. The FDA, in particular, maintains oversight of the formulation, manufacture, distribution, packaging, and labeling of all of our products. The Drug Enforcement Administration, or DEA, maintains oversight over our products that are considered controlled substances.

From February 5, 2019 through February 12, 2019, our Amphastar facility in Rancho Cucamonga, California was subject to a preapproval inspection by the FDA. The inspection included a review of our corrective actions taken from the previous cGMP inspection in March 2017, as well as review of data to support our pending applications. The inspections resulted in multiple observations on Form 483. We fully responded to those observations on March 6, 2019. We believe that our responses to the observations will satisfy the requirements of the FDA and that no significant further actions will be necessary.

From February 25 through March 1, 2019, our IMS facility in South El Monte, California was subject to a preapproval inspection by the FDA. The inspection included a review of our corrective actions taken from the 2017 inspection as well as review of data to support our pending applications. The inspection resulted in multiple observations on Form 483. We responded to those observations on March 22, 2019. We believe that our responses to the observations will satisfy the requirements of the FDA and that no significant further actions will be necessary.

From July 23 through July 25, 2019, our Amphastar facility in Rancho Cucamonga, California was subject to a routine, post-marketing adverse drug experience reporting inspection, or PADE, by the FDA. The inspection included a review of our processes for collecting, reviewing, investigating and reporting post-marketing adverse drug experiences reported through various sources. The inspection resulted in no Form 483 findings. No further actions will be necessary.

From August 27 through September 04, 2019, one of our California clinical trial sites was subject to a pre-approval biomonitoring inspection by the FDA. The inspection included a review of the clinical trial data to support one of our pending applications. The inspection resulted in no Form 483 findings. No further actions will be necessary.

From October 7 through October 11, 2019, our Chinese subsidiary ANP, was subject to a cGMP inspection by the FDA. The inspection included a review of compliance with FDA regulations relating to Good Manufacturing Practices. The inspection resulted in one observation on Form 483. We responded to that observation. We believe that our response to the observation will satisfy the requirements of the FDA and that no significant further actions will be necessary.

From October 24 to November 5, 2019, our IMS facility in South El Monte, California was subject to a preapproval inspection by the FDA. The inspection included a review of data to support our pending applications. The inspection resulted in observations on Form 483. We will respond to those observations within the required timeframe. We believe that our responses to the observations will satisfy the requirements of the FDA and that no significant further actions will be necessary.

Market risk

As filed, 4,584 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following discussion provides forward-looking quantitative and qualitative information about our potential exposure to market risk. Market risk represents the potential loss arising from adverse changes in the value of financial instruments. The risk of loss is assessed based on the likelihood of adverse changes in fair values, cash flows or future earnings. We are exposed to market risk for changes in the market values of our investments (Investment Risk), the impact of interest rate changes (Interest Rate Risk), and the impact of foreign currency exchange changes (Foreign Currency Exchange Risk).

Investment Risk

We regularly review the carrying value of our investments and identify and recognize losses, for income statement purposes, when events and circumstances indicate that any declines in the fair values of such investments below our accounting basis are other than temporary. As of September 30, 2019, none of our investments experienced any declines in fair value that are other than temporary. We do not enter into investments for trading or speculative purposes.

As of September 30, 2019, we had $28.3 million deposited in seven banks located in China, $4.3 million deposited in one bank located in France, and $0.8 million deposited in one bank located in the United Kingdom. We also maintained $42.6 million in cash equivalents that include money market accounts as of September 30, 2019. Additionally, we maintain approximately $3.8 million in corporate bonds as of September 30, 2019. The remaining amounts of our cash equivalent as of September 30, 2019, are in non-interest bearing accounts.

Interest Rate Risk

Our primary exposure to market risk is interest‑rate‑sensitive investments and credit facilities, which are affected by changes in the general level of U.S. interest rates. Due to the nature of our short-term investments, we believe that we are not subject to any material interest rate risk with respect to our short-term investments.

As of September 30, 2019, we had $45.0 million in long-term debt and finance leases outstanding. Of this amount, $11.5 million had variable interest rates which were not locked-in through fixed interest rate swap contracts. The debt with variable interest rate exposure had a weighted-average interest rate of 5.3% at September 30, 2019. An increase in the index underlying these rates of 1% (100 basis points) would increase our annual interest expense on the debt with variable interest rate exposure by approximately $0.1 million per year.

Foreign Currency Exchange Risk

Our finished pharmaceutical products are primarily sold in the U.S. domestic market, and have little exposure to foreign currency price fluctuations. However, as a result of our acquisition of the API manufacturing business in Éragny-sur-Epte, France, we are exposed to market risk related to changes in foreign currency exchange rates. Specifically, our insulin sales contracts are frequently denominated in euros, which are subject to fluctuations relative to the USD.

Our Chinese subsidiary, ANP, maintains its books of record in Chinese yuan. These books are remeasured into the functional currency of USD, using the current or historical exchange rates. The resulting currency remeasurement adjustments and other transactional foreign exchange gains and losses are reflected in our statement of operations.

Our French subsidiary, AFP, maintains its books of record in euros. Our U.K. subsidiary, IMS UK, maintains its books of record in British pounds. The results of operations are translated to USD at the average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing exchange rate at the date of the equity transactions. Translation adjustments are reflected in stockholders’ equity and are included as a component of other comprehensive income (loss).

We are also exposed to the potential earnings effects from intercompany foreign currency assets and liabilities that arise from normal trade receivables and payables and other intercompany loans.

As of September 30, 2019, a 10% unfavorable change in the exchange rate of the U.S. dollar strengthening against the foreign currencies to which we have exposure would result in approximately $3.2 million reduction of foreign currency gains, and approximately $3.5 million reduction in other comprehensive income.

As of September 30, 2019, our foreign subsidiaries had cash balances denominated in foreign currencies of $7.0 million.

Controls and procedures

As filed, 3,232 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

Our management, under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer, our principal executive and principal financial officers, respectively, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934, as amended, as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that as of such date, our disclosure controls and procedures were effective (a) to ensure that information that we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (b) to include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2019, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act).

Inherent Limitations of Internal Controls

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management overriding of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Risk factors

As filed, 3,907 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Except as noted below, there were no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the Securities and Exchange Commission on March 15, 2019.

Some of our products are marketed without FDA approval and may be subject to enforcement actions by the FDA.

A number of our prescription products are marketed without FDA approval. These products, like many other prescription drugs on the market that the FDA has not formally evaluated as being effective, contain active ingredients that were first marketed prior to the enactment of the Federal Food, Drug and Cosmetic Act, or FFDCA. The FDA has assessed these products in a program known as the “Prescription Drug Wrap-Up” and has stated that these drugs cannot be lawfully marketed unless they comply with certain “grandfather” exceptions to the definition of “new drug” in the FFDCA. These exceptions have been strictly construed by FDA and by the courts, and the FDA has stated that it is unlikely that any of the unapproved prescription drugs on the market, including certain of our drugs, qualify for the exceptions. At any time, the FDA may require that some or all of our unapproved prescription drugs be submitted for approval and may direct us to recall these products and/or cease marketing the products until they are approved. The FDA may also take enforcement actions based on our marketing of these unapproved products, including but not limited to the issuance of an untitled letter or a warning letter, and a judicial action seeking an injunction, product seizure and/or civil or criminal penalties. The enforcement posture could change at any time and our ability to market such drugs could terminate with little or no notice. Moreover, if our competitors seek and obtain approval and market FDA-approved prescription products that compete against our unapproved prescription products, we would be subject to a higher likelihood that the FDA may seek to take action against our unapproved products. Such competitors have brought and may bring claims against us alleging unfair competition or related claims.

As a result of our meetings with the FDA in 2009, we decided to discontinue all of our products that were subject to the Prescription Drug Wrap-Up program, with the exception of epinephrine in vial form. These products were all produced at our subsidiary, IMS. During the third quarter of 2010, the FDA requested that we reintroduce several of the withdrawn products to cope with a drug shortage, while we prepared and filed applications for approval of the products. Between August and October, 2010, we reintroduced atropine, morphine, dextrose, and epinephrine prefilled syringes.

In February 2017, the FDA requested that we discontinue the manufacturing and distribution of our epinephrine injection, USP vial product, which had been marketed under the “grandfather” exception to the FDA’s Prescription Drug Wrap-Up program. We discontinued selling this product in the second quarter of 2017.

For the years ended December 31, 2018, 2017, and 2016, we recorded net revenues of $26.4 million, $22.0 million, and $17.4 million, respectively, from our unapproved products. For the nine months ended September 30, 2019 and 2018, we recorded net revenues of $29.1 million and $19.8 million, respectively, from our unapproved products. Our unapproved products currently on the market include: atropine, morphine, dextrose and epinephrine prefilled syringes. We have filed three ANDAs and one NDA with respect to our remaining unapproved products in order to mitigate all risk associated with the marketing of unapproved drug products. Prior to the approval of our ANDA and NDA submissions, we continue to operate in compliance with the FDA Compliance Policy Guide, CPG Sec. 440.100 Marketed New Drugs Without Approved NDAs and ANDAs.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2019-07-01 to 2019-09-30$80.1mus-gaap:Revenues
Revenue9 months2019-01-01 to 2019-09-30$239.0mus-gaap:Revenues
Cost of revenue3 months2019-07-01 to 2019-09-30$44.9mus-gaap:CostOfRevenue
Cost of revenue9 months2019-01-01 to 2019-09-30$140.4mus-gaap:CostOfRevenue
Gross profit3 months2019-07-01 to 2019-09-30$35.3mus-gaap:GrossProfit
Gross profit9 months2019-01-01 to 2019-09-30$98.5mus-gaap:GrossProfit
Research and development3 months2019-07-01 to 2019-09-30$18.6mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2019-01-01 to 2019-09-30$49.2mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2019-07-01 to 2019-09-30$2.4mus-gaap:OperatingIncomeLoss
Operating income9 months2019-01-01 to 2019-09-30$205.0kus-gaap:OperatingIncomeLoss
Interest expense3 months2019-07-01 to 2019-09-30$22.0kus-gaap:InterestExpense
Interest expense9 months2019-01-01 to 2019-09-30$76.0kus-gaap:InterestExpense
Income tax3 months2019-07-01 to 2019-09-30$598.0kus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2019-01-01 to 2019-09-30$13.3mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2019-07-01 to 2019-09-30$1.3mus-gaap:NetIncomeLoss
Net income9 months2019-01-01 to 2019-09-30$50.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2019-07-01 to 2019-09-30$0.03us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2019-01-01 to 2019-09-30$1.00us-gaap:EarningsPerShareDiluted
Basic EPS3 months2019-07-01 to 2019-09-30$0.03us-gaap:EarningsPerShareBasic
Basic EPS9 months2019-01-01 to 2019-09-30$1.06us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2019-07-01 to 2019-09-3050,075,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2019-01-01 to 2019-09-3050,128,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2019-01-01 to 2019-09-30$36.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2019-01-01 to 2019-09-30$33.1mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases9 months2019-01-01 to 2019-09-30$8.5mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2019-09-30$85.6mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2019-09-30$268.9mus-gaap:AssetsCurrent
Total assetsAt period end2019-09-30$585.6mus-gaap:Assets
Current liabilitiesAt period end2019-09-30$86.6mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-09-30$152.0mus-gaap:Liabilities
Shareholders' equityAt period end2019-09-30$389.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001297184-19-000044. Last ingested by Listed: Nov 6, 2026, 17:01 ET. Listed shows no prices and gives no investment advice.